Table 4. Effects of mTOR and PI3K inhibitors on the constitutive release of angioregulatory mediators by primary human AML cells.
| Soluble mediator | Rapamycin | Temsirolimus | GDC-0941 | 3-MA |
|---|---|---|---|---|
| CXCL8 | 96.5 % 0.4737 |
103.0 % 0.8218 |
66.0 % 0.0004 |
93.5 % 0.1502 |
| CXCL9 | 76.0 % 0.2048 |
69.0 % 0.0317 |
50.0 % 0.0047 |
32.5 % 0.0009 |
| CXCL10 | 50.5 0.0003 |
52.0 0.0002 |
53.0 0.0007 |
29.0 0.0001 |
| CXCL11 | 70.5 0.0226 |
81.0 0.183 |
56.5 0.0311 |
35.0 0.0005 |
| Ang-1 | 89.0 0.0270 |
89.0 0.0195 |
76.0 <0.0001 |
71.0 <0.0001 |
| Ang-2 | 97.0 0.3164 |
88.0 0.1682 |
85.0 0.0006 |
79.0 0.0014 |
| VEGF | 64.0 0.1665 |
41.0 0.0051 |
51.0 0.0255 |
86.0 0.5621 |
| HGF | 75.0 0.0020 |
72.0 0.0001 |
57.5 <0.0001 |
57.0 <0.0001 |
| MMP-2 | 96.0 0.1640 |
70.5 0.0123 |
54.3 0.0002 |
58.5 0.0009 |
| MMP-9 | 64.5 0.0004 |
60.0 0.0010 |
59.0 <0.0001 |
83.5 0.0207 |
The results are presented as the median % inhibition (upper value) of mediators released after drug treatment compared to levels in control cultures without drugs. The corresponding p-value (lower value) is shown where statistically significant differences are marked in bold. The drugs were tested at the following concentrations: rapamycin 1.0 μM, temsirolimus 0.1 μM, GDC-0941 1.0 μM and 3-MA 1.0 mM).